Presystemic metabolism of AZ'0908, a novel mPGES-1 inhibitor: An in vitro and in vivo cross-species comparison

Journal of Pharmaceutical Sciences

Volumn 102, Issue 3, 2013, Pages 1106-1115

  Bylund, Johan ^a,b   Bueters, Tjerk ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

ABC transporters; Bioavailability; CYP2J2; First pass metabolism; Interspecies correlation; Intestinal loss; Intestinal metabolism; Pharmacokinetics

Indexed keywords

1 AMINOBENZOTRIAZOLE; AZ 0908; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2J2; ISOMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; NONHUMAN;

EID: 84878124595     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23443     Document Type: Article

References (40)

1. Bylund J, Ek ME, Holenz J, Johansson MH, Kers A, Narhi K, Nordvall G, Ohberg L, Sohn D, Viklund, von Berg S. 2009. Patent WO/2009/064250.
2. Samuelsson B, Morgenstern R, Jakobsson PJ. 2007. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev 59:207-224.
3. Hellriegel ET, Bjornsson TD, Hauck WW. 1996. Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther 60:601-607.
4. Fisher MB, Labissiere G. 2007. The role of the intestine in drug metabolism and pharmacokinetics: An industry perspective. Curr Drug Metab 8:694-699.
5. Thomas VH, Bhattachar S, Hitchingham L, Zocharski P, Naath M, Surendran N, Stoner CL, El-Kattan A. 2006. The road map to oral bioavailability: An industrial perspective. Expert Opin Drug Metab Toxicol 2:591-608.
6. Lennernäs H. 2008. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: Experience from in vivo dissolution and permeability studies in humans. Curr Drug Metab 8:645-657.
7. Yang J, Jamei M, Rowland Yeo K, Tucker GT, Rostami-Hodjegan A. 2007. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
8. Gertz M, Harrison A, Houston JB, Galetin A. 2010. Prediction of human intestinal first-pass metabolism of 25 CYP3A4 substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
9. Kadono K, Akabane T, Tabata K, Gato K, Terashita S, Teramura T. 2010. Quantitative prediction of intestinal metabolism in humans from a simplified intestinal availability model and empirical scaling factor. Drug Metab Dispos 38:1230-1237.
10. Nishimuta H, Sato K, Yabuki M, Komura S. 2011. Prediction of the intestinal first-pass metabolism of CYP3A and UGT substrates in humans from in vitro data. Drug Metab Pharmacokinet 26:592-601.
11. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. 2010. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the Advanced Dissolution, Absorption, Metabolism (ADAM) model. Curr Drug Metab 11:716-729.
12. Shugarts S, Benet LZ. 2009. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm Res 26:2039-2054.
13. Zamek-Gliszczynski MJ, Bedwell DW, Bao JQ, Higgins JW. 2012. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics. Drug Metab Dispos 40:1825-1833.
14. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y. 2012. Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 166:1793-1803.
15. Beéry E, Rajnai Z, Abonyi T, Makai I, Bánsághi S, Erdo F, Sziráki I, Herédi-Szabó K, Kis E, Jani M, Márki-Zay J, Tóth K G, Krajcsi P. 2012. ABCG2 modulates chlorothiazide permeability in vitro-characterization of its interactions. Drug Metab Pharmacokinet 27:349-353.
16. Bueters T, Juric S, Sohlenius-Sternbeck A-K, Hu Y, Bylund J. Rat predicts the combined non-absorbed and presystemically metabolised fractions in human poorly. Xenobiotica, In press.
17. Chiou WL, Barve A. 1998. Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats. Pharm Res 15:1792-1795.
18. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin H-C, Lennernas H, Zhong Y, Amidon GL, Yu LX, Sun D. 2006. Why it is challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686.
19. Sietsema WK. 1989. The absolute oral bioavailability of selected drugs. Int J Clin Pharmacol Ther Toxicol 27:179-211.
20. Komura H, Iwaki M. 2011. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: Species differences. Drug Metab Rev 43:476-498.
21. Patil AG, D'Souza R, Dixit N, Damre A. 2011. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer. Eur J Drug Metab Pharmacokinet 36:115-119.
22. Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P. 2009. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816-1831.
23. Mease K, Sane R, Podila L, Taub ME. 2012. Differential selectivity of effluxtransporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2. J Pharm Sci 101:1888-1897.
24. Sohlenius-Sternbeck A-K, Afzelius L, Prusis P, Neelissen J, Hoogstraate J, Johansson J, Floby E, Bengtsson A, Gissberg O, Sternbeck J, Petersson C. 2010. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40, 637-649.
25. Bueters T, Dahlström J, Kvalvågnaes K, Betner I, Briem S. 2011. High-throughput analysis of standardized pharmacokinetic studies in the rat using sample pooling and UPLC-MS/MS. J Pharm Biomed Anal 55:1120-1126.
26. Balani SK, Zhu T, Yang TJ, Liu Z, He B, Lee FW. 2002. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in rats, dogs, and monkeys. Drug Metab Dispos 30:1059-1062.
27. El-Kattan AF, Poe J, Buchholz L, Thomas HV, Brodfuehrer J, Clark A. 2008. The use of 1-aminobenzotriazole in differentiating the role of CYP-mediated first pass metabolism and absorption in limiting drug oral bioavailability: A case study. Drug Metab Lett 2:120-124.
28. Riley RJ, McGinnity DF, Austin RP. 2005. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab Dispos 33:1304-1311.
29. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
30. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. 2010. Methodologies for investigating drug metabolism at the early drug discovery stage: Prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11:678-685.
31. Linder CD, Renaud NA, Hutzler JM. 2009. Is 1-aminobenzotriazole an appropriate in vitro tool as a nonspecific cytochrome P450 inactivator? Drug Metab Dispos 37:10-13.
32. Strelevitz TJ, Foti RS, Fisher MB. 2006. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: Varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance. J Pharm Sci 95:1334-1341.
33. Neuhoff S, Artursson P, Zamora I, Ungell AL. 2006. Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells. Pharm Res 23:350-359.
34. Damre A, Mallurwar SR, Behera D. 2009. Preparation and characterization of rodent intestinal microsomes: Comparative assessment of two methods. Indian J Pharm Sci 71:75-77.
35. Galetin A, Houston JB. 2006. Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: Impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 318:1220-1229.
36. Thelen K, Dressman JB. 2009. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 61:541-558.
37. Wu S, Moomaw CR, Tomer KB, Falck JR, Zeldin DC. 1996. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271:3460-3468.
38. Lee CA, Neul D, Clouser-Roche A, Dalvie D, Wester MR, Jiang Y, Jones JP 3rd, Freiwald S, Zientek M, Totah RA. 2010. Identification of novel substrates for human cytochrome P450 2J2. Drug Metab Dispos 38:347-356.
39. Zeldin DC, Foley J, Goldsworthy SM, Cook ME, Boyle JE, Ma J, Moomaw CR, Tomer KB, Steenbergen C, Wu S. 1997. CYP2J subfamily cytochrome P450s in the gastrointestinal tract: Expression, localization, and potential functional significance. Mol Pharmacol 51:931-943.
40. Zhang QY, Ding X, Dunbar D, Cao L, Kaminsky LS. 1999. Induction of rat small intestinal cytochrome P-450 2J4. Drug Metab Dispos 27:1123-1127.